Display options
Cite
Adams S, Robbins FM, Chen D, et al. HLA class I and II genotype of the NCI-60 cell lines. J Transl Med. 2005;3(1):11doi: 10.1186/1479-5876-3-11.
Adams, S., Robbins, F. M., Chen, D., Wagage, D., Holbeck, S. L., Morse, H. C., Stroncek, D., & Marincola, F. M. (2005). HLA class I and II genotype of the NCI-60 cell lines. Journal of translational medicine, 3(1), 11. https://doi.org/10.1186/1479-5876-3-11
Adams, Sharon, et al. "HLA class I and II genotype of the NCI-60 cell lines." Journal of translational medicine vol. 3,1 (2005): 11. doi: https://doi.org/10.1186/1479-5876-3-11
Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC, Stroncek D, Marincola FM. HLA class I and II genotype of the NCI-60 cell lines. J Transl Med. 2005 Mar 04;3(1):11. doi: 10.1186/1479-5876-3-11. PMID: 15748285; PMCID: PMC555742.
Copy Download .nbib Format: NLM
Share it on

J Transl Med. 2005 Mar 04;3(1):11. doi: 10.1186/1479-5876-3-11.

HLA class I and II genotype of the NCI-60 cell lines.

Journal of translational medicine

Sharon Adams, Fu-Meei Robbins, Deborah Chen, Devika Wagage, Susan L Holbeck, Herbert C Morse, David Stroncek, Francesco M Marincola

Affiliations

  1. Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, 20892, USA. [email protected].

PMID: 15748285 PMCID: PMC555742 DOI: 10.1186/1479-5876-3-11

Abstract

Sixty cancer cell lines have been extensively characterized and used by the National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools for anti-cancer drug development. An extensive database has been accumulated that could be used to select individual cells lines for specific experimental designs based on their global genetic and biological profile. However, information on the human leukocyte antigen (HLA) genotype of these cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2) check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in which knowledge of HLA molecule expression is relevant. Since genome-based typing does not guarantee actual surface protein expression, further characterization of relevant cell lines should be entertained to verify surface expression in experiments requiring correct antigen presentation.

References

  1. Cancer Cell. 2004 Aug;6(2):129-37 - PubMed
  2. J Transl Med. 2003 Nov 26;1(1):9 - PubMed
  3. Science. 1992 Oct 16;258(5081):447-51 - PubMed
  4. Cytometry. 2002 Jan 1;47(1):46-9 - PubMed
  5. Science. 1997 Jan 17;275(5298):343-9 - PubMed
  6. Cancer Chemother Pharmacol. 2000;45(5):409-16 - PubMed
  7. J Exp Med. 2000 Mar 20;191(6):961-76 - PubMed
  8. J Chem Inf Comput Sci. 2004 Jan-Feb;44(1):249-57 - PubMed
  9. Semin Oncol. 1992 Dec;19(6):622-38 - PubMed
  10. Cancer Res. 2003 Dec 15;63(24):8634-47 - PubMed
  11. J Cancer Res Clin Oncol. 1995;121(9-10):495-500 - PubMed
  12. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10787-92 - PubMed
  13. J Nat Prod. 2004 May;67(5):783-92 - PubMed
  14. Genome Biol. 2003;4(12):R82 - PubMed
  15. Br J Cancer. 2001 May 18;84(10):1424-31 - PubMed
  16. J Transl Med. 2004 Sep 13;2(1):30 - PubMed
  17. Chem Biol. 2001 Jan;8(1):71-80 - PubMed
  18. Int J Cancer. 2005 Mar 20;114(2):283-90 - PubMed
  19. J Immunol. 1998 Jul 15;161(2):877-89 - PubMed
  20. Cancer Cell. 2004 Aug;6(2):105-7 - PubMed
  21. N Engl J Med. 2000 Nov 9;343(19):1408-9 - PubMed
  22. J Natl Cancer Inst. 1998 Jun 3;90(11):862 - PubMed
  23. Clin Cancer Res. 2003 Jan;9(1):59-67 - PubMed
  24. Anticancer Res. 1992 Jul-Aug;12(4):1035-53 - PubMed
  25. J Natl Cancer Inst. 1991 Jun 5;83(11):757-66 - PubMed
  26. Prog Clin Biol Res. 1988;276:265-86 - PubMed
  27. Nat Genet. 2000 Mar;24(3):236-44 - PubMed
  28. Anticancer Drug Des. 1997 Oct;12(7):533-41 - PubMed
  29. J Med Chem. 2000 Apr 20;43(8):1550-62 - PubMed
  30. Nat Genet. 2000 Mar;24(3):227-35 - PubMed
  31. Mol Med Today. 1999 Apr;5(4):178-86 - PubMed
  32. Cancer Immunol Immunother. 2001 Mar;50(1):3-15 - PubMed
  33. Nucleosides Nucleotides. 1999 Jun-Jul;18(6-7):1729-30 - PubMed
  34. Immunol Today. 1995 Oct;16(10):487-94 - PubMed
  35. Dis Markers. 2001;17(2):77-88 - PubMed
  36. Genomics. 2000 Nov 15;70(1):113-22 - PubMed
  37. J Immunother. 1998 Jan;21(1):1-16 - PubMed
  38. Bioinformatics. 2002 Mar;18(3):405-12 - PubMed
  39. J Immunol. 1994 Aug 1;153(3):1225-37 - PubMed
  40. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34 - PubMed
  41. C R Biol. 2003 Oct-Nov;326(10-11):909-20 - PubMed
  42. Pharmacogenomics J. 2002;2(4):259-71 - PubMed
  43. J Exp Med. 1999 Jul 19;190(2):205-15 - PubMed
  44. Vaccine. 2001 Mar 21;19(17-19):2607-14 - PubMed
  45. Cancer Res. 1997 Oct 1;57(19):4285-300 - PubMed

Publication Types